Health Care · Pharmaceutical Preparations

GOSS Gossamer Bio, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 1728117109 filings
Russell 2000

GOSS at a glance

Gossamer Bio, Inc. (GOSS, SEC CIK 1728117) filed its latest 10-K annual report on March 17, 2026, a 10-Q quarterly report on November 10, 2026, an 8-K current report on November 10, 2026 and Form 4 insider filings as recently as September 25, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Gossamer Bio, Inc. (GOSS) reported revenue of $48.5 million (down 57.7% from FY2024) and a net loss of $170.4 million. Diluted EPS was -$0.75.
  • As of June 30, 2026, 23 institutional investment managers tracked by SignalX reported holding Gossamer Bio, Inc. (GOSS) shares worth $16.7 million in 13F-HR filings.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$48.5M
−57.7% vs prior year
Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
23 funds
$16.7M · +0 vs prior quarter
Latest 8-K
Nov 10, 2026
Item 2.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Revenue $38.4M, up $25.1M YoY from $13.3M, driven by $37.1M contract-liability release
  • Operating margin 18.7% vs (369.4)% YoY, reflecting operating income $7.2M vs loss $49.1M
  • Seralutinib largest development program, R&D expense $18.2M vs $45.5M YoY
  • Cash, cash equivalents and marketable securities $51.2M at September 30, 2026, funding operations into Q1 2027
  • Operating cash use $107.7M, August private placement provided $25.0M, NDA acceptance and capital needs remain key uncertainties

Risk Factors

  • Regulatory risk: PROSERA missed its primary endpoint, potentially prompting FDA rejection, added studies, or narrower seralutinib labeling
  • Filing risk: FDA may refuse NDA filing despite September 2026 submission and favorable Pre-NDA meeting interpretation
  • Liquidity risk: Missed NDA Acceptance Milestone could eliminate approximately $125.0 million Second Closing proceeds by December 31, 2026
  • Financing risk: Purchase Agreement restrictions may limit additional equity fundraising if the Second Closing fails
  • Development risk: Additional FDA-required studies could delay approval and increase seralutinib development costs

AI summary of the GOSS 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 10, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 financial results for quarter ended September 30, 2026
  • Full results and management commentary in Exhibit 99.1 press release

Item EX-99.1: Item EX-99.1

  • First NDA submitted for seralutinib in PAH, creating a major regulatory catalyst ahead of potential FDA filing acceptance and approval
  • FDA acceptance could unlock up to approximately $125 million in additional committed capital, supporting potential 2027 commercialization
Filed Oct 28, 2026Full analysis →

Item 5.07: Submission of Matters to a Vote of Security Holders

  • Stockholders approved potential share issuance exceeding 20% of pre-closing shares under the August 20, 2026 Purchase Agreement
  • Approval covers Pre-Funded Warrants, FDA Approval Warrants, and Series A-1, A-2, and A-3 Preferred Stock conversions
Filed Sep 28, 2026Full analysis →

Item 8.01: Other Events

  • Nasdaq minimum bid-price deficiency cured; continued listing on Nasdaq Global Select Market preserved
  • Compliance followed 1-for-80 reverse stock split effective September 10, 2026

AI summaries of GOSS 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for GOSS

Don't miss the next GOSS filing

  • Alerts as it files. A push when GOSS files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut GOSS, by share count.
  • Ask anything. An AI agent that reads every GOSS filing and answers with sources.

GOSS alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Cox Russell J.ASep 23, 2026-
Daniel Thomas OASep 23, 2026-
Drynan SkyeASep 23, 2026-
Milligan SandraASep 23, 2026-
Ciongoli Gregory AustinASep 23, 2026-
Quisel John DASep 23, 2026-
Nathan Steven DASep 23, 2026-
Peterson CarynAAug 24, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$114.7M$48.5M
Operating Income--$59.9M-$170.7M
Net Income--$56.5M-$170.4M
Op. Margin--52.2%-352.2%
Net Margin--49.3%-351.5%
Balance Sheet
Total Assets-$315.3M$172.2M
Equity$62.8M$29.5M-$122.8M
ROE--191.7%138.8%
Per Share
EPS$-1.18$-0.25$-0.75
Cash Flow
Operating CF-$159.2M-$3.5M-$171.3M
CapEx$0$0$79K

Source: XBRL data in Gossamer Bio, Inc. (GOSS)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q2 2026

Aggregate GOSS share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
GOSS shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q2 202623$16.7M
Q1 202623$18.7M
Q4 202524$192.2M
Q3 202523$139.4M
Q2 202524$53.3M
Q1 202517$29.2M
Q4 202411$23.3M
Position changes: Q1 2026 → Q2 2026
Top Buyers
Top Sellers
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 145 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

GOSS filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
10-QNov 10, 2026Analysis
8-KNov 10, 2026Analysis-
8-KOct 28, 2026Analysis-
8-KSep 28, 2026Analysis-
4Sep 25, 2026--
4Sep 25, 2026--
4Sep 25, 2026--
4Sep 25, 2026--
4Sep 25, 2026--
4Sep 25, 2026--
4Sep 25, 2026--
8-KSep 23, 2026Analysis-
8-KSep 16, 2026Analysis-
8-KSep 11, 2026Analysis-
8-KSep 9, 2026Analysis-
8-KSep 3, 2026Analysis-
4Aug 26, 2026--
4Aug 26, 2026--
8-KAug 26, 2026Analysis-
4Aug 26, 2026--
4Aug 26, 2026--
4Aug 26, 2026--
8-KAug 21, 2026Analysis-
10-QAug 13, 2026Analysis
8-KAug 13, 2026Analysis-

Related Health Care companies

All Health Care →

GOSS SEC filings: frequently asked questions

Which institutions hold GOSS stock?

As of June 30, 2026, the largest Gossamer Bio, Inc. (GOSS) holders among the 13F filers tracked by SignalX were D.E. Shaw & Co ($6.7 million), AQR Capital Management ($2.6 million), Renaissance Technologies LLC ($1.9 million), Vanguard Capital Management LLC ($1.6 million), BlackRock ($1.3 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was GOSS's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Gossamer Bio, Inc. (GOSS) reported revenue of $48.5 million (down 57.7% from FY2024) and a net loss of $170.4 million. Diluted EPS was -$0.75. The figures come from the XBRL data in the 10-K.

What did GOSS report in its latest 8-K?

Gossamer Bio, Inc. (GOSS) filed an 8-K on November 10, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 financial results for quarter ended September 30, 2026.

What are the latest GOSS SEC filings?

Gossamer Bio, Inc. (GOSS) filed its latest 10-K annual report on March 17, 2026, a 10-Q quarterly report on November 10, 2026, an 8-K current report on November 10, 2026 and a Form 4 insider filing on September 25, 2026.

What is GOSS's SEC CIK number?

Gossamer Bio, Inc. (GOSS)'s SEC Central Index Key (CIK) is 1728117. EDGAR lists every GOSS filing under that number.

Ask anything about GOSS

The research agent reads GOSS's filings, financials, insider trades and 13F holders, then answers with sources.